SCM
Superstring Capital Management Portfolio holdings
AUM
$80.3M
This Quarter Return
+21.19%
1 Year Return
+68.23%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$151M
AUM Growth
+$151M
(+7.9%)
Cap. Flow
+$8M
Cap. Flow
% of AUM
5.29%
Top 10 Holdings %
Top 10 Hldgs %
64.45%
Holding
47
New
17
Increased
12
Reduced
7
Closed
10
Top Buys
| 1 |
Nkarta
NKTX
|
$9.1M |
| 2 |
Cytokinetics
CYTK
|
$7.1M |
| 3 |
Savara
SVRA
|
$6.23M |
| 4 |
Cabaletta Bio
CABA
|
$4.96M |
| 5 |
BridgeBio Pharma
BBIO
|
$4.55M |
Top Sells
| 1 |
IMGN
Immunogen Inc
IMGN
|
$17.7M |
| 2 |
Protagonist Therapeutics
PTGX
|
$8.69M |
| 3 |
Immunovant
IMVT
|
$8.58M |
| 4 |
Neurocrine Biosciences
NBIX
|
$3.87M |
| 5 |
Lantheus
LNTH
|
$3.4M |
Sector Composition
| 1 | Healthcare | 96.62% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Cytokinetics
CYTK
$4.23B
| $19.6M | 12.93% |
278,915
+101,312
| +57% | +$7.1M |
|
|
2
Nkarta
NKTX
$151M
| $12.9M | 8.5% |
1,189,193
+841,812
| +242% | +$9.1M |
|
3
89bio
ETNB
$1.34B
| $11M | 7.24% |
941,287
-80,190
| -8% | -$933K |
|
|
4
BridgeBio Pharma
BBIO
$9.89B
| $10.9M | 7.23% |
353,507
+147,181
| +71% | +$4.55M |
|
|
5
Savara
SVRA
$567M
| $10.3M | 6.8% |
2,065,144
+1,250,878
| +154% | +$6.23M |
|
6
IDEAYA Biosciences
IDYA
$2.15B
| $9.53M | 6.3% |
217,070
-34,225
| -14% | -$1.5M |
|
7
Fate Therapeutics
FATE
$120M
| $6.76M | 4.47% |
920,476
+72,653
| +9% | +$533K |
|
8
Day One Biopharmaceuticals
DAWN
$769M
| $5.78M | 3.82% |
349,679
-29,947
| -8% | -$495K |
|
9
Roivant Sciences
ROIV
$8.15B
| $5.6M | 3.7% |
531,019
+204,858
| +63% | +$2.16M |
|
10
Ionis Pharmaceuticals
IONS
$6.79B
| $5.24M | 3.47% |
120,896
-68,722
| -36% | -$2.98M |
|
|
MRNS
11
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
| $5.11M | 3.38% |
565,550
+103,106
| +22% | +$932K |
|
|
12
Cabaletta Bio
CABA
$133M
| $4.96M | 3.28% |
+290,797
| New | +$4.96M |
|
13
UroGen Pharma
URGN
$900M
| $4.32M | 2.86% |
288,267
+32,837
| +13% | +$493K |
|
|
VRNA
14
Verona Pharma
VRNA
$9.16B
| $4.17M | 2.76% |
259,383
+135,343
| +109% | +$2.18M |
|
|
JBIO
15
Jade Biosciences, Inc. Common Stock
JBIO
$258M
| $3.26M | 2.16% |
+110,264
| New | +$3.26M |
|
16
Apogee Therapeutics
APGE
$2.17B
| $2.98M | 1.97% |
+44,868
| New | +$2.98M |
|
17
Axsome Therapeutics
AXSM
$6.05B
| $2.92M | 1.93% |
36,607
+20,428
| +126% | +$1.63M |
|
18
Dyne Therapeutics
DYN
$1.92B
| $2.83M | 1.87% |
+99,822
| New | +$2.83M |
|
19
Praxis Precision Medicines
PRAX
$958M
| $2.45M | 1.62% |
+40,119
| New | +$2.45M |
|
20
Allogene Therapeutics
ALLO
$251M
| $2.33M | 1.54% |
521,249
+299,137
| +135% | +$1.34M |
|
21
Keros Therapeutics
KROS
$618M
| $2.24M | 1.48% |
33,828
-40,821
| -55% | -$2.7M |
|
22
Pyxis Oncology
PYXS
$79.4M
| $2.1M | 1.39% |
+493,759
| New | +$2.1M |
|
23
Ascendis Pharma
ASND
$11.8B
| $1.93M | 1.27% |
+12,754
| New | +$1.93M |
|
24
PepGen
PEPG
$38M
| $1.68M | 1.11% |
+114,385
| New | +$1.68M |
|
25
Tourmaline Bio
TRML
$601M
| $1.6M | 1.06% |
+69,972
| New | +$1.6M |
|